Equity · Healthcare
AMRX
NASDAQAmneal Pharmaceuticals (AMRX)
The line runs 17.65 USD on 12 August through 21.29 USD on 9 November, on a scale from 16 to 22. Days the market did not trade hold the previous close, flat.
- Market cap
- 7.4B USD
- P/E (TTM)
- 51.9
- Revenue, year to Dec 2025
- 3.0B USD
- EPS, diluted, year to Dec 2025
- 0.22 USD
- 52-week range
- 11 USD – 21.51 USD
- Avg volume
- 162.7K
as of Nov 9, 2026
Have Amneal Pharmaceuticals (AMRX) insiders bought or sold shares recently?
In the 90 days to 10 Nov 2026, Amneal Pharmaceuticals insiders reported 3 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 12 Nov 2025, show no open-market purchase.
Form 4, 90 days to 10 Nov 2026, newest reported trade 13 Aug 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 13 Aug 2026 | Kiely JohnDirector | Sell | 50,000 | 882K USD |
| 12 Aug 2026 | Daly Jason B.EVP, Chief Legal Officer | Sell | 210,000 | 3.7M USD |
| 12 Aug 2026 | Shah NikitaExecutive Vice President | Sell | 146,403 | 2.6M USD |
| Sold | 3 open-market sales | 406,403 | $7.10M |
5 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 17 Sep 2026 | BUCHI J KEVINDirector | Gift | 20,445 | |
| 11 Sep 2026 | BUCHI J KEVINDirector | Option exercise | 20,445 | 295K USD |
| 01 Sep 2026 | BOYER ANDREW SExecutive Vice President | Gift | 80,000 | |
| 21 Aug 2026 | BOYER ANDREW SExecutive Vice President | Gift | 152,426 | |
| 13 Aug 2026 | Kiely JohnDirector | Gift | 10,000 |
Which funds hold Amneal Pharmaceuticals (AMRX)?
7 of the 45 institutional funds we track reported a Amneal Pharmaceuticals position for the quarter ended 30 Jun 2026 — a combined 59.8M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Citadel Advisors | Added | 1,118,715 | 19.4M USD | +93.7% |
| AQR Capital Management | Held (±25%) | 795,028 | 13.8M USD | −8.1% |
| D. E. Shaw & Co. | Trimmed | 774,055 | 13.4M USD | −55.0% |
| Balyasny Asset Management | Added | 434,132 | 7.5M USD | +448.7% |
| Two Sigma Investments | Held (±25%) | 233,270 | 4.0M USD | −17.5% |
| Renaissance Technologies | Trimmed | 87,487 | 1.5M USD | −68.4% |
| Millennium Management | Trimmed | 14,761 | 256K USD | −96.0% |
| Man Group | Exited | |||
| Point72 Asset Management | Exited |
What has been filed or recorded for Amneal Pharmaceuticals (AMRX)?
The filings we hold for Amneal Pharmaceuticals, newest first: 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Sep 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.06 USD | |
| 30 Sep 2026 | Financials | Total assets | 5.3B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 531.3M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS 0.18 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 0.19 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 0.22 USD | |
| 31 Dec 2025 | Financials | Revenue | 3.0B USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 72.1M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 0.22 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 0.01 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS 0.07 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS 0.04 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −0.38 USD |
What do people ask about Amneal Pharmaceuticals (AMRX)?
What did Amneal Pharmaceuticals shares close at?21.29
Amneal Pharmaceuticals closed at 21.29 USD on 9 Nov 2026, up 5.71% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Amneal Pharmaceuticals’ market cap?7.4B
Amneal Pharmaceuticals is worth 7.4B USD by market value as of 9 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Amneal Pharmaceuticals’ P/E ratio?51.9
Amneal Pharmaceuticals has a price-to-earnings ratio of 51.9, as of 9 Nov 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is Amneal Pharmaceuticals’ revenue?3.0B
Amneal Pharmaceuticals reported revenue of 3.0B USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Amneal Pharmaceuticals insiders bought or sold shares recently?3 sales
In the 90 days to 10 Nov 2026, Amneal Pharmaceuticals insiders reported 3 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 12 Nov 2025, show no open-market purchase. A further 5 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Amneal Pharmaceuticals?7 of 45
7 of the 45 funds we track reported a Amneal Pharmaceuticals position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Citadel Advisors, AQR Capital Management and D. E. Shaw & Co. See Funds
When did Amneal Pharmaceuticals last report earnings?−0.06
Amneal Pharmaceuticals last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.06 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings